Jpmorgan Chase & CO Daxor Corp Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Daxor Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5 shares of DXR stock, worth $45. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 5
-0.0%
Holding current value
$45
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DXR
# of Institutions
11Shares Held
87.3KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA48.8KShares$440,4280.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8KShares$133,6850.0% of portfolio
-
Keyes, Stange & Wooten Wealth Management, LLC Palm Coast, FL14.6KShares$131,8000.07% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ7.2KShares$64,9440.0% of portfolio
-
Ubs Group Ag1.24KShares$11,1480.0% of portfolio
About DAXOR CORP
- Ticker DXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 4,041,670
- Market Cap $36.5M
- Description
- Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used i...